THERANEXUS: BBDF-101 added to our scenario, now waiting for IND early next year | CORPORATE | EUR13 vs. Under Review
THERANEXUS - CORPORATE | EUR13 vs. Under ReviewBBDF-101 added to our scenario, now waiting for IND early next year
BBDF-101: first sales expected for 2024, EUR200m at peak
Some adjustments for THN102, but our confidence remains intact
New FV of EUR13, but THN102’s deal is key to finance BBDF-101
Theranexus SA is a France-based company engaged in the healthcare industry. The Company is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The Company's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.